Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Rabin

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|January 28, 2020
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosisOliver C Cohen, Faye Sharpley, Julian D Gillmore, et al.
British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Leukemia & Lymphoma|June 1, 2023
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experienceGeorge Nesr, Raakhee Shah, Charalampia Kyriakou, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 16, 2020
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosisOliver C Cohen, Maximillian H Brodermann, Iona J Blakeney, et al.
Blood Cancer Journal|September 5, 2022
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosisJahanzaib Khwaja, Joshua Bomsztyk, Shameem Mahmood, et al.
British Journal of Haematology|October 11, 2021
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factorsWei Yee Chan, Lara Howells, William Wilson, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
British Journal of Haematology|October 12, 2021
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trialWei Yee Chan, Nicholas Counsell, Ruth de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|January 28, 2020
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosisOliver C Cohen, Faye Sharpley, Julian D Gillmore, et al.
British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Leukemia & Lymphoma|June 1, 2023
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experienceGeorge Nesr, Raakhee Shah, Charalampia Kyriakou, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 16, 2020
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosisOliver C Cohen, Maximillian H Brodermann, Iona J Blakeney, et al.
Blood Cancer Journal|September 5, 2022
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosisJahanzaib Khwaja, Joshua Bomsztyk, Shameem Mahmood, et al.
British Journal of Haematology|October 11, 2021
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factorsWei Yee Chan, Lara Howells, William Wilson, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
British Journal of Haematology|October 12, 2021
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trialWei Yee Chan, Nicholas Counsell, Ruth de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III TrialMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
BMJ Open|June 2, 2022
<i>F</i>railty-adjusted therapy <i>i</i>n <i>T</i>ransplant <i>N</i>on-<i>E</i>ligible patient<i>s</i> with newly diagno<i>s</i>ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trialAmy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, et al.
Pageof 8